Abbott

Healthcare that works

Abbott Park, Illinois, U.S.

Abbott is a market leader in RPM with device portfolio.

Abbott hero image

Shareable draft

Check out Abbott on @MedStartr Today Abbott is a market leader in RPM with device portfolio. #Diabetes #CardiovascularHealth #InfectiousDiseases #NeurologicalDisorders #Gastroenterology #WomenSHealth #NutritionRelatedConditions #BloodDisorders #TraumaticBrainInjury #CancerOncology #MedicalDevices #MedMo #MedStartrVentures

https://www.medstartr.ai/s/7FUIeR5la58

Get Involved in Abbott

How We Help

Core Technology

Continuous Glucose Monitoring (CGM), Advanced Medical Devices, Diagnostic Platforms, Molecular Diagnostics, Pharmaceutical Formulations, Biowearables

Key Differentiators

Diversified Portfolio, Innovation and R&D (invested $2.4 billion in R&D in 2021), Global Presence (operates in over 160 countries), Strong Brand Equity (e.g., FreeStyle Libre, Similac, Ensure, Glucerna), Operational Scale and Manufacturing Footprint (across approximately 90 sites), Patient-Centric Solutions, Strategic Acquisitions and Divestitures, Diagnostic Capabilities

Clinical Focus

Diabetes care, structural heart conditions, cardiac rhythm management, heart failure monitoring, vascular health, neuromodulation, infectious disease diagnostics, nutritional support, gastroenterology, women's health, cardiometabolic disorders, pain management, central nervous system disorders, respiratory health, oncology, blood disorders, traumatic brain injury.

Target Customers

Patients, healthcare providers (physicians, hospitals, clinics), consumers, governments, and emerging markets.

Product Stage

Mature

Company Info

Business Model: Diversified healthcare model with four main segments: Medical Devices (diabetes care, structural heart, cardiac rhythm management, vascular, neuromodulation), Diagnostics (core lab, molecular, point-of-care, rapid diagnostics, transfusion medicine), Nutritional Products (pediatric, adult, specialty nutrition), and Established Pharmaceuticals (off-patent branded generics primarily in emerging markets).
Founded: 1888
Website: www.abbott.com

Disease Areas

Diabetes Cardiovascular Health Infectious Diseases Neurological Disorders Gastroenterology Women's Health Nutrition-Related Conditions Blood Disorders Traumatic Brain Injury Cancer & Oncology

Technologies

Glucose MonitoringAdvanced Medical DevicesDiagnostic PlatformsMolecular DiagnosticsPharmaceutical FormulationsBiowearables

Clinical & IP

🔬

Clinical Validation

FreeStyle Libre published in NEJM with HbA1c reductions. AVEIR dual-chamber pacemaker: 98% implant success. Tendyne TMVR FDA approved May 2025. Comprehensive peer-reviewed trials across all therapeutic areas.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Abbott?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.